

REVENIO

Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen

Revenio Group Corporation, Managers' transactions, August 5, 2022 at 5.30 p.m. (EEST)

Revenio Group Oyj: Managers' Transactions – Robin Pulkkinen

Person subject to the notification requirement

Name: Robin Pulkkinen

Position: Chief Financial Officer

Issuer: Revenio Group Oyj

LEI: 743700127EoFWSXLKK04

Notification type: INITIAL NOTIFICATION

Reference number: 18240/7/6

Transaction date: 2022-08-04

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009010912

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 200 Unit price: 53 EUR

(2): Volume: 505 Unit price: 54.6 EUR

(3): Volume: 250 Unit price: 53.2 EUR

(4): Volume: 200 Unit price: 55 EUR

(5): Volume: 200 Unit price: 54 EUR

Aggregated transactions

(5): Volume: 1355 Volume weighted average price: 54.07601 EUR

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

www.revenio.fi

Distribution

Nasdaq Helsinki Ltd

Main media

www.revenio.fi

REVENIO

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen](#)